Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
NCT04982445
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
CABENUVA
Sponsor
ViiV Healthcare